Search Results
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
LBL-034LBL-034 is a bispecific T-cell engager (TCE) that targets both GPRC5D and CD3, developed using the Company's proprietary LeadsBody platform. Designed with a 2:1 binding format—two sites for GPRC5D and one for CD3—LBL-034 can selectively target GPRC5D+ cancer cells, conditionally activate T cells, reduce the
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted CAR-T cell therapy product, Equecabtagene Autoleucel (Eque-cel), for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple
More news about: IASO Bio
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
heterogeneity and treatment resistance associated with single-target drugs, reducing tumor escape. Meanwhile, its optimized CD3 affinity enables precise T-cell activation for tumor killing while also improving safety. In the disclosed Phase 1 study results, IBI3003 showed a manageable safety profile and
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented
More news about: CARsgen Therapeutics
Dec 07, 2025, 16:49 ET El neumático con descuento celebra el Campeonato Inter Miami CF MLS Cup
Acerca de Discount TireDiscount Tire es un minorista independiente líder de neumáticos, ruedas y limpiaparabrisas. Fundada en 1960 por Bruce T. Halle, la empresa atiende a clientes en más de 1250 tiendas en 39 estados. La compañía opera como Discount Tire en la mayor parte de los EE. UU. y como
More news about: Discount Tire
Dec 07, 2025, 13:24 ET The 4th China International Supply Chain Expo Set for Beijing in June 2026
multimedia:https://www.prnewswire.com/news-releases/c-o-r-r-e-c-t-i-o-n----china-international-supply-chain-expo-302634807.html
More news about: China International Supply Chain Expo
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
rituximab.Treatment with ORN-252 led to complete peripheral and splenic B cell depletion in NHP at doses as low as 0.1 mg/kg.CAR+ T cells upregulated cytotoxicity markers after the first dose when the majority of cell killing occurs.ORN-252 demonstrated durable B cell depletion
More news about: Orna Therapeutics
Dec 07, 2025, 05:18 ET In Quebec: Janette Bertrand presenteert een progamma op haar 100ste!
https://mma.prnewswire.com/media/2839608/Soci_t__de_t_l_diffusion_du_Qu_bec_Au_Qu_bec%C2%A0__Janette_Bertrand.mp4Foto -
More news about: Société de télédiffusion du Québec
Dec 07, 2025, 04:21 ET CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included
More news about: CARsgen Therapeutics
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
China.[iii]In the updated NRDL, limertinib is newly listed for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), who have previously experienced disease progression during or after treatment with EGFR TKI; and 2) the
More news about: Innovent Biologics
Dec 06, 2025, 17:31 ET Discount Tire Celebrates Inter Miami CF MLS Cup Championship
together."About Discount TireDiscount Tire is a leading independent retailer of tires, wheels, and windshield wipers. Founded in 1960 by Bruce T. Halle, the company serves customers at more than 1,250 stores in 39 states. The company does business as Discount Tire in most of the U.S. and as America's
More news about: Discount Tire
Dec 06, 2025, 17:13 ET Discount Tire Celebrates Inter Miami CF MLS Cup Championship
together."About Discount TireDiscount Tire is a leading independent retailer of tires, wheels, and windshield wipers. Founded in 1960 by Bruce T. Halle, the company serves customers at more than 1,250 stores in 39 states. The company does business as Discount Tire in most of the U.S. and as America's
More news about: Discount Tire
Dec 06, 2025, 16:41 ET Resource Growth Programs Gain Momentum as Gold Holds Above $4,200
Ontario. The Fork Deposit currently contains an Indicated mineral resource of 20,900 ounces grading 5.3 g/t gold with an additional Inferred resource of 49,500 ounces grading 5.2 g/t gold, with infill drilling focused on a shallow, high-grade, low-plunging zone of gold mineralization defined over
More news about: Equity Insider
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an
More news about: Vivacta Biotechnology Co., Ltd.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
lenalidomide.CARVYKTI® is a BCMA-directed, genetically modified autologous T-cell immunotherapy that involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR-positive T cells to eliminate cells that express BCMA. BCMA is primarily expressed
More news about: Johnson & Johnson
Dec 05, 2025, 18:00 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in
More news about: Nektar Therapeutics
Dec 05, 2025, 16:48 ET Au Québec : Janette Bertrand moderiert eine Sendung mit 100 Jahren!
https://mma.prnewswire.com/media/2839608/Soci_t__de_t_l_diffusion_du_Qu_bec_Au_Qu_bec%C2%A0__Janette_Bertrand.mp4Foto -
More news about: Société de télédiffusion du Québec
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
of SunRISe-1, 7 patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer. Three patients (3.5%) had progression determined at the time of cystectomy. The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days. Magnetic
More news about: Johnson & Johnson
Dec 05, 2025, 14:27 ET CCTV+ : À la rencontre de la culture Hehe
Taizhou, dans la province de Zhejiang, et s'est lancé dans l'exploration de la culture Hehe. Quelles expériences le berceau de la culture Hehe offrira-t-il à cet ami étranger ?
More news about: CCTV+
Dec 05, 2025, 13:19 ET Au Québec : Janette Bertrand anime une émission à 100 ans!
https://mma.prnewswire.com/media/2839608/Soci_t__de_t_l_diffusion_du_Qu_bec_Au_Qu_bec%C2%A0__Janette_Bertrand.mp4Photo -
More news about: Société de télédiffusion du Québec
Dec 05, 2025, 13:13 ET SIERRA7 RECEIVES 2025 PLATINUM HIRE VETS MEDALLION AWARD FROM US DEPARTMENT OF LABOR
CMMI-SVC Level 3-appraised member of the government technology and services industry, Sierra7 holds critical federal government prime contracts, including T4NG, VHA-IHT, GSA VETS 2, NIH CIO-SP3, NASA SEWP V, VA TeleCare Companion, and several GSA schedules. Sierra7 is certified in ISO 9001:2015 Quality Management
More news about: Sierra7, Inc
Dec 05, 2025, 11:00 ET The Dot Corp Expands Services With New Promotional Products & Apparel Division
format graphics, direct mail campaigns, eCommerce ordering, and kit assembly. The Promotional Products & Apparel division extends that model so that T shirts, hoodies, event swag, and premium gifts can be planned, produced, packed, and shipped alongside postcards, brochures, signage, and packaging.The
More news about: The Dot Corp
Dec 05, 2025, 10:47 ET Beyond the Game: Edward Jones and Big 12 Drive Lasting Impact Across 16 Communities
/PRNewswire/ -- The Edward Jones and Big 12 Conference's partnership will take center stage at the Edward Jones® Big 12 Football Championship game at AT&T Stadium in Arlington, Texas, on Saturday, Dec. 6. While the action on the field promises to excite, Edward Jones is harnessing this moment to provide
More news about: Edward Jones
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
using two critical time points: t1, when seizures are abnormally prolonged, and t2, when long-term consequences may occur. Overall, median total seizure durations were ≤t2 for most seizure categories, with a high proportion of patients achieving SE termination by or before t2. There were low rates of seizure
More news about: Neurelis, Inc.
Dec 05, 2025, 08:42 ET CGTN : Ce qui fait de la coopération entre la Chine et la France un succès à double sens
grand pays et s'offrir mutuellement compréhension et soutien sur les questions concernant les intérêts fondamentaux et les préoccupations majeures, a-t-il déclaré lors d'une rencontre avec la presse en compagnie de M. Macron.La France attache une grande importance à ses relations avec la Chine
More news about: CGTN